Tag Archives: investment

Soaring stocks and the reasons why (BONT, JAH, VMW)

Posted on January 24, 2012 by Cameron White

In this report: Bon-Ton Stores (NASDAQ:BONT), Jarden Corp. (NYSE:JAH) and Vmware (NYSE:VMW).

Bon-Ton Stores (NASDAQ:BONT) shares soared today after news was released that the company’s President and CEO Bud Bergren is stepping down and that former Lord & Taylor …

Posted in Latest Headlines, Reports | Tagged analyst, Bon-Ton Stores, BONT, CEO, common shares, credit rating, earned, earnings, estimates, expectations, investment, investor, JAH, Jarden Corp., Moody's, NASDAQ, NASDAQ:BONT, net income, NYSE, NYSE:JAH, NYSE:VMW, president, profits, quarter, report, repurchase program, revenue, shares, Standard & Poor, VMW, Vmware, Wall Street | Comments Off

Bank of America returns to profit despite investment banking losses and litigation expenses

Posted on January 19, 2012 by Josie Middleton

Bank of America (NYSE:BAC) is trading nearly 5 percent higher today after the company returned to a fourth quarter profit amidst large legal expenses related to mortgages and losses from its investment banking business. The bank was able to offset …

Posted in Financial, Main Post | Tagged Analysts, BAC, Bank, Bank of America, bond, business, company, debt, investment, lawsuits, losses, market, mortgages, net income, NYSE, NYSE:BAC, profit, quarter, revenue, share, stock, trading, Wall Street | Comments Off

Bank of New York Mellon slips after missing target in 4Q

Posted on January 18, 2012 by Cameron White

Bank of New York Mellon Corp. (NYSE:BNY) is trading over 3.7 percent lower today after the company reported a 26 percent drop in fourth quarter net income as restructuring charges and lower revenue from less client activity hurt financials. The …

Posted in Financial, Main Post | Tagged Analysts, Bank of New York Mellon, BNY, company, earned, expectations, fees, financials, investment, net income, NYSE, NYSE:BNY, quarter, reported, restructuring, revenue, share, trading, Wall Street | Comments Off

What’s up Voxx International, Virtus Investment Partners and Capital One Financial?

Posted on January 10, 2012 by Martin Timble

In this report: Voxx International Corp. (NASDAQ:VOXX), Virtus Investment Partners (NASDAQ:VRTS) and Capital One Financial Corp. (NYSE:COF).

Voxx International Corp. (NASDAQ:VOXX) is trading over 17 percent higher today after the company reported its third quarter financials that beat analyst expectations. …

Posted in Latest Headlines, Reports | Tagged acquisition, analyst, Capital One Financial Corp., carters, COF, company, earnings, expectations, FBR, financials, income, investment, NASDAQ, NASDAQ:VOXX, NASDAQ:VRTS, NYSE, NYSE:COF, pending, quarter, report, S&P, sales, smallcap, top picks, trading, Virtus Investment Partners, VOXX, Voxx International Corp., VRTS | Comments Off

What the fuss Google, Oracle and Achillion Pharmaceuticals?

Posted on January 9, 2012 by Cameron White

In this report: Achillion Pharmaceuticals (NASDAQ:IDIX), Google (NASDAQ:GOOG) and Oracle (NASDAQ:ORCL).

Achillion Pharmaceuticals (NASDAQ:IDIX) and other Hepatitis C drug makers soared on Monday morning after Inhibitex (NASDAQ:INHX) became a $2.5 billion acquisition target for Bristol Myers Squibb (NYSE:BMY). The move, …

Posted in Latest Headlines, Reports | Tagged Achillion Pharmaceuticals, acquisition, Analysts, BMO Capital, BMY, Bristol-Myers Squibb, CEO, downgrade, drug, financial, firm, GOOG, Google, hepatitis C, IDIX, Inhibitex, investment, investors, Motorola Mobility Holdings, NASDAQ, nasdaq:goog, NASDAQ:IDIX, NASDAQ:ORCL, Oracle, ORCL, quarter, rating, report, sales, smartphone, treatments | Comments Off

What’s up Idenix Pharmaceuticals, Vivus and Broadcom?

Posted on January 9, 2012 by Martin Timble

In this report: Idenix Pharmaceuticals (NASDAQ:IDIX), Broadcom Corp. (NASDAQ:BRCM) and Vivus (NASDAQ:VVUS).

Idenix Pharmaceuticals (NASDAQ:IDIX) and Hepatitis C drug maker soared on Monday morning after Inhibitex (NASDAQ:INHX) became a $2.5 billion acquisition target for Bristol Myers Squibb (NYSE:BMY). The …

Posted in Latest Headlines, Reports | Tagged Analysts, BMY, BRCN, Bristol-Myers Squibb, Broadcom Corp., Buy, contraindication, Deutsche Bank, drug, FDA, firm, hepatitis C, Idenix Pharmaceuticals, IDIX, Inhibitex, INHX, investment, market, NASDAQ, NASDAQ:BRCM, NASDAQ:IDIX, NASDAQ:INHX, NASDAQ:VVUS, NYSE, NYSE:BMY, obesity, Qnexa, rating, upgrade, Vivus, VVUS | Comments Off

Stock Market Quotes and Streaming Charts - QuoteDaddy.com Level 2 Stock Quotes from Quote Daddy on Vimeo.

blogs

Lorimer Wilson Analyst

Dian L. Chu "EconMatters"

Paul Ebeling Trading News

Warren Bevan Precious Metals

eStocksDaily.com ("ESD") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities customers should buy or sell for themselves. The employees or affiliates of ESD may hold positions in the stocks or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities. ESD, the authors, the publisher, and all affiliates of ESD assume no responsibility or liability for your trading and investment results. Factual statements on the ESD's website, or in its publications, are made as of the date stated and are subject to change without notice. For ESD full disclaimer and disclosure go to our disclaimer page.It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by ESD are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of ESD's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on ESD's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.